论文部分内容阅读
考察使用cytodex-3微载体共培养人脐带血(UCB)来源的造血干细胞(HSCs)和间充质干细胞(MSCs)的可行性,并评价其应用于未来临床治疗中的可能性.考虑到临床应用的安全性要求,尝试采用采集于UCB的人自体血清(HAS)取代目前广泛使用的胎牛血清(FBS),以期在体外共培养后可同时获得UCB-HSCs和UCB-MSCs.由于MSCs贴附的cytodex-3载体与悬浮的HSCs之间的密度差异,在共培养后自由沉降分离这两种不同类型的干细胞将会十分容易.为优化培养条件,评估了用不同含量的HAS(2.8%、5.6%、8.3%和11.1%)对UCB-MSCs和UCB-HSCs扩增的影响.结果表明,5.6%HAS培养UCB-HSCs最优,扩增倍数达(1.88±0.33)倍,且同时对UCB-MSCs的扩增亦无很大影响.因此,共培养条件下的HAS最佳含量约为5.6%.所研发的共培养体系可为临床应用提供扩增的UCB-HSCs和UCB-MSCs.
To investigate the feasibility of using cytodex-3 microcarriers to co-culture human umbilical cord blood (UCB) -based hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) and to evaluate their potential application in future clinical treatment.Considering clinical At the same time, UCB-HSCs and UCB-MSCs can be obtained simultaneously after co-culture in vitro by using autologous serum from human UCB (HAS) to replace the currently used fetal bovine serum (FBS) Differences in density between the cytodex-3 vector and the suspended HSCs will make it very easy to freely sediment and isolate these two different types of stem cells after co-culture.In order to optimize the culture conditions, different concentrations of HAS (2.8% , 5.6%, 8.3%, and 11.1%, respectively) on UCB-MSCs and UCB-HSCs.The results showed that 5.6% HAS cultured UCB-HSCs had the best multiplication factor of 1.88 ± 0.33, Therefore, the best content of HAS in co-culture is about 5.6% .The developed co-culture system can provide expanded UCB-HSCs and UCB-MSCs for clinical application.